Gastrointestinal stromal tumor in 2020 or suddenly a lot of news
Doc. MUDr. Jan Novotný, Ph.D.
Onkologi, Sunderby Sjukhus, Luieá, Švédsko
The advances in molecular biology of gastrointestinal stromal tumors (GIST) in recent years has allowed to distinguish various tumor subtypes that respond differently to anticancer therapy. This fact together with the development of new active drugs has led to the changes in standards of care in both adjuvant and palliative settings.
GIST, imatinib, pazopanib, regorafenib, ripretinib, PDGFR, NF1, SDH
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...